TY - JOUR T1 - Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine JF - bioRxiv DO - 10.1101/2021.01.15.426463 SP - 2021.01.15.426463 AU - Yasunori Watanabe AU - Luiza Mendonça AU - Elizabeth R. Allen AU - Andrew Howe AU - Mercede Lee AU - Joel D. Allen AU - Himanshi Chawla AU - David Pulido AU - Francesca Donnellan AU - Hannah Davies AU - Marta Ulaszewska AU - Sandra Belij-Rammerstorfer AU - Susan Morris AU - Anna-Sophia Krebs AU - Wanwisa Dejnirattisai AU - Juthathip Mongkolsapaya AU - Piyada Supasa AU - Gavin R. Screaton AU - Catherine M. Green AU - Teresa Lambe AU - Peijun Zhang AU - Sarah C. Gilbert AU - Max Crispin Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/01/19/2021.01.15.426463.abstract N2 - Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.Competing Interest StatementOxford University has entered into a partnership with Astra Zeneca for further development of ChAdOx1 nCoV-19. SCG is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and consultant to Vaccitech. ER -